Schonfeld Strategic Advisors LLC Wave Life Sciences Ltd. Transaction History

Schonfeld Strategic Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.38 - $6.48 $449,541 - $665,074	102,635 New	102,635 $512,000
Q1 2023 May 15, 2023	BUY	$3.58 - $6.3 $40,096 - $70,560	11,200 New	11,200 $48,000
Q4 2020 Feb 16, 2021	SELL	$6.99 - $9.26 $335,520 - $444,480	-48,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$8.49 - $19.54 $204,609 - $470,914	-24,100 Reduced 33.43%	48,000 $0
Q2 2020 Aug 14, 2020	BUY	$7.44 - $11.29 $536,424 - $814,008	72,100 New	72,100 $750,000
Q2 2019 Aug 14, 2019	SELL	$22.93 - $42.84 $1.54 Million - $2.87 Million	-67,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$32.69 - $47.91 $1.54 Million - $2.25 Million	47,000 Added 235.0%	67,000 $2.6 Million
Q3 2018 Nov 14, 2018	SELL	$36.35 - $55.2 $363,500 - $552,000	-10,000 Reduced 33.33%	20,000 $1 Million
Q2 2018 Aug 14, 2018	SELL	$33.85 - $50.65 $344,017 - $514,755	-10,163 Reduced 25.3%	30,000 $1.15 Million
Q1 2018 May 15, 2018	SELL	$32.45 - $54.7 $1.43 Million - $2.42 Million	-44,193 Reduced 52.39%	40,163 $1.61 Million
Q4 2017 Feb 14, 2018	BUY	$21.8 - $39.35 $1.84 Million - $3.32 Million	84,356	84,356 $2.96 Million

164

117M

148K

109K

Ticker WVE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,820,096
Market Cap $1.24B
Description
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.